G(M3) Ganglioside

13 trials

Sponsors

Center of Molecular Immunology(CIM), Center of Molecular Immunology (CIM), Center for Genetic Engineering and Biotechnology (CIGB), in Havana.

Conditions

Acquired immunodeficiency syndrome (AIDS)Advanced non small cell lung cancerBreast cancer IIa, IIb and IIIa surgically treated with positive gangliaCancer of ovary, fallopian tubes and / or peritoneum.HIV/AIDSHepatocellular carcinomaMetastatic Breast CancerMetastatic hormone-receptor positive and HER2 negative breast cancer

Early Phase 1

Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory

Active, not recruitingRPCEC00000279

Center of Molecular Immunology (CIM)Advanced non small cell lung cancer

Start: 2018-07-09Updated: 2026-03-30

Phase 1

Dose scale-up and cohort expansion with the therapeutic mAb 14F7

Active, not recruitingRPCEC00000204

Center of Molecular Immunology (CIM)Solid tumors Solid tumors

Start: 2016-01-01Target: 60Updated: 2026-03-30

Phase 2

NGcGM3/VSSP/Montanide ISA 51 vaccine in metastatic breast cancer. Phase II

Active, not recruitingRPCEC00000068

Center of Molecular Immunology (CIM)Metastatic Breast Cancer

Start: 2002-08-27Target: 80Updated: 2026-03-30

NAcGM3/VSSP/Montanide ISA 51 formulation in HIV, phase II.

RecruitingRPCEC00000015

Center of Molecular Immunology(CIM)HIV/AIDS

Start: 2008-02-21Target: 118Updated: 2026-03-30

NAcGM3/VSSP-aids-patients drug resistant to antiretroviral treatment-Phase I-II

Active, not recruitingRPCEC00000213

Center of Molecular Immunology (CIM)Acquired immunodeficiency syndrome (AIDS)

Start: 2015-01-28Target: 25Updated: 2026-03-30

NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer

Active, not recruitingRPCEC00000218

Center of Molecular Immunology (CIM)Metastatic triple negative breast cancer

Start: 2016-10-14Target: 45Updated: 2026-03-30

NGcGM3/VSSP in small cell lung cancer

RecruitingRPCEC00000224

Center of Molecular Immunology (CIM)Small cell lung cancer

Start: 2017-04-01Target: 40Updated: 2026-03-30

NGcGM3/VSSP in Metastatic melanoma

RecruitingRPCEC00000223

Center of Molecular Immunology (CIM)Metastatic melanoma

Start: 2014-03-11Target: 160Updated: 2026-03-30

CENTAURO-6 Study

Active, not recruitingRPCEC00000237

Center for Genetic Engineering and Biotechnology (CIGB), in Havana.Hepatocellular carcinoma

Start: 2017-04-03Target: 20Updated: 2026-03-30

Phase 3

NGcGM3/VSSP/Montanide ISA 51 vaccine for breast cancer IIa, IIb and IIIa surgically treated with positive ganglia and disease-free, Phase IIb/III.

RecruitingRPCEC00000070

Center of Molecular Immunology (CIM)Breast cancer IIa, IIb and IIIa surgically treated with positive ganglia

Start: 2007-04-17Target: 744Updated: 2026-03-30

NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer

Active, not recruitingRPCEC00000220

Center of Molecular Immunology (CIM)Metastatic hormone-receptor positive and HER2 negative breast cancer

Start: 2017-02-01Target: 286Updated: 2026-03-30

CENTAURO-4 Study

Active, not recruitingRPCEC00000246

Center for Genetic Engineering and Biotechnology (CIGB), in Havana.Cancer of ovary, fallopian tubes and / or peritoneum.

Start: 2017-05-02Target: 40Updated: 2026-03-30

Unknown Phase

Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC)

Active, not recruitingRPCEC00000270

Center of Molecular Immunology (CIM)Non Small Cell Lung Cancer

Start: 2018-04-30Target: 30Updated: 2026-03-30